An Updated Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) Versus Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Georg Hess,Eva Gine,Ana Nunes,Pier Luigi Zinzani,Luca Fischer,Gilles Salles,Vittorio Ruggero Zilioli,Juan-Manuel Sancho,Mats Jerkeman,Adam Vilmar,Kim M Linton,Lucie Oberic,Stephan Stilgenbauer,Anke Ohler,Julie E Park,Sam Keeping,Jonathan Lambert,James J Wu,John Reitan,Toby A Eyre,Ana Jimenez-Ubieto,Jenny M H Chen,Martin Dreyling,Catherine Thieblemont,Sally W Wade

doi:10.1016/j.jtct.2023.12.502

An Updated Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) Versus Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Georg Hess, Eva Gine + Show 23 more

https://doi.org/10.1016/j.jtct.2023.12.502

Copy DOI

Journal: Biology of Blood and Marrow Transplantation

Publication Date: Feb 1, 2024

#Covalent Bruton Tyrosine Kinase Inhibitor #CAR T-cell + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

An Updated Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) Versus Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Full Text